Tobacco Regulation and Products

Share

In 2009, we won a hard-fought campaign that led to Congress passing a law granting the U.S. Food and Drug Administration (FDA) the authority to regulate all tobacco products, including cigarettes, e-cigarettes, cigars and hookah. Yet, it took the FDA seven years to begin their oversight of many of these products with much more work left to be done. 

Recent spikes in the use of e-cigarettes makes clear that more must be done to regulate tobacco products and the industry's deceptive marketing practices.  We are working to ensure the government fully leverages the regulatory power it now possesses to protect children and adults. 

Tobacco use costs our nation nearly $300 billion in health care and productivity losses each year.

Take Action

Protect our Children from Big Tobacco

The tobacco industry has preyed upon young people by marketing products that appeal to kids.

Latest Updates

September 5, 2024
National

WASHINGTON, D.C. – New data from the U.S. Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention’s National Youth Tobacco Survey found that 1.63 million youth reported using e-cigarettes. There is an encouraging decrease in high school use rates, while middle school use rates

June 21, 2024
California

A tobacco retail licensing program takes effect to hold tobacco retailers in Clovis accountable for following state and local laws, by facing strong penalties, including fines, license suspension and revocation, if they fail to do so.

June 21, 2024
National

Today, the Food and Drug Administration (FDA) dealt a blow to public health by authorizing the sale of four menthol e-cigarettes manufactured by NJOY LLC.

May 20, 2024
National

Nearly 20 years ago, a U.S. Federal District judge found that the major cigarette manufacturers violated civil racketeering laws for deliberately defrauding the public. Big Tobacco knew their products were harmful, and lied to the public for decades about the health risks and addictiveness of cigarettes and their targeting to

Tobacco Regulation and Products Resources

Whether Puff Bar is under the jurisdiction of the Center for Drug Evaluation and Research
(CDER) as a drug or the Center for Tobacco Products (CTP) as a tobacco product, it is critical that
FDA take action and not permit this company and this product to escape regulatory oversight.
Puff Bar has neither been approved as a drug nor received a premarket tobacco product order.
The agency should not allow any perceived regulatory “gap” to enable this company or any
other company to market new addictive nicotine products without going through the legally
required FDA review by either CDER or CTP.

Because JUUL’s products continue to have the largest share of the e-cigarette market, and therefore presumably are undergoing expedited review, we write at this time to express our conclusion that based on all of the publicly available evidence, no JUUL product currently on the market can meet the statutory public health standard. Therefore, they should not receive a marketing order.